Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul/Aug;11(4):286-292.
doi: 10.1097/ADM.0000000000000310.

Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact

John R Brooklyn  1 , Stacey C Sigmon
Affiliations

Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact

John R Brooklyn et al. J Addict Med. 2017 Jul/Aug.

Abstract

Background: Opioid use disorders (OUDs) are reaching epidemic proportions in the United States, and many geographic areas struggle with a persistent shortage in availability of opioid agonist treatment. Over the past 5 years, Vermont addiction medicine physicians and public health leaders have responded to these challenges by developing an integrated hub-and-spoke opioid treatment network.

Methods: In the present report, we review the development, implementation, and impact of this novel hub-and-spoke model for expanding OUD treatment in Vermont.

Results: Vermont's hub-and-spoke system has been implemented state-wide and well-received by providers and patients alike. Adoption of this model has been associated with substantial increases in the state's OUD treatment capacity, with Vermont now having the highest capacity for treating OUD in the United States with 10.56 people in treatment per 1000. There has been a 64% increase in physicians waivered to prescribe buprenorphine, a 50% increase in patients served per waivered physician, and a robust bidirectional transfer of patients between hubs and spokes based upon clinical need. Challenges to system implementation and important future directions are discussed.

Conclusions: Development and implementation of a hub-and-spoke system of care has contributed substantially to improvements in opioid agonist treatment capacity in Vermont. This system may serve as a model for other states grappling with the current opioid use epidemic.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: There are no financial disclosures relevant to this study.

Figures

FIGURE 1
FIGURE 1
Components and referral sources for an integrated hub-and-spoke system for addiction treatment.
FIGURE 2
FIGURE 2
Treatment Needs Questionnaire (for online/digital appendix). @2015 JR Brooklyn & SC Sigmon, Licensed under CC BY-NC-ND 4.0 version 1/21/16.
FIGURE 3
FIGURE 3
Patient census data presented for Vermont’s 5 regional hubs over time (January 2013–September 2015).
FIGURE 4
FIGURE 4
Total number of individuals served in hubs and number of individuals waiting for treatment over time (January 2014–August 2015).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amass L, Bickel WK, Crean JP, et al. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacol. 1998;136:217–225. - PubMed
    1. Barry DT, Bernard MJ, Beitel M, et al. Counselors’ experiences treating methadone-maintained patients with chronic pain: a needs assessment study. J Addict Med. 2008;2:108–111. - PubMed
    1. Becker WC, Fiellin DA. Provider satisfaction with office-based treatment of opioid dependence: a systematic review. Substance Abuse. 2006;26:15–22. - PubMed
    1. Becker WC, Sullivan LE, Tetrault JM, et al. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94:38–47. - PubMed
    1. Bickel WK, Amass L, Crean JP, et al. Buprenorphine dosing every 1, 2 or 3 days in opioid-dependent patients. Psychopharmacol. 1999;146:111–118. - PubMed